Bristol-Myers Squibb: Multiple Sclerosis trials

The registry lists 18 Multiple Sclerosis studies with Bristol-Myers Squibb as lead sponsor. 4 are open to participants now and 6 have results posted.

Phase 1 3Phase 2 3Phase 3 7Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to ZeposiaRecruitingNCT07732907
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityRecruitingNCT06782490Phase 2
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisRecruitingNCT06408259Phase 3
• A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their OffspringRecruitingNCT05170126
• A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple SclerosisTerminatedNCT05064436Phase 1Results posted
• Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying TherapyCompletedNCT05028634Phase 3Results posted
• A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisCompletedNCT02576717Phase 3Results posted
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)CompletedNCT02294058Phase 3Results posted
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisCompletedNCT02047734Phase 3Results posted
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis PatientsCompletedNCT01628393Phase 2/3Results posted
• A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisActive, not recruitingNCT06396039Phase 4
• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Active, not recruitingNCT06220201Phase 1
• A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their InfantsActive, not recruitingNCT06133049
• A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT05658601
• A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)CompletedNCT05335031
• Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)TerminatedNCT04140305Phase 3
• Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMSCompletedNCT02797015Phase 1
• A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple SclerosisTerminatedNCT00035529Phase 2